Mallinckrodt PLC (NYSE:MNK)

1.64
Delayed Data
As of 3:59pm ET
 +0.145 / +9.73%
Today’s Change
1.00
Today|||52-Week Range
6.42
-53.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$247.0M

Company Description

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Contact Information

Mallinckrodt Plc
College Business & Technology Park
Blanchardstown Dublin 15
P:(531) 696-0000
Investor Relations:

Employees

Shareholders

Other institutional45.28%
Mutual fund holders33.87%
Individual stakeholders21.60%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Bryan M. ReasonsChief Financial Officer & Executive Vice President
Steven Joseph RomanoChief Scientific Officer & Executive VP
Babatunde Adekunle OtulanaChief Medical Officer & Senior Vice President
Michele RobertsonChief Compliance Officer & Senior Vice President